Perrigo Company plc (0Y5E.L)
USD 26.0
(-2.11%)
USD 26.0
(-2.11%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 646.2 Million USD | 27.88% |
| 2022 | 507.2 Million USD | -42.27% |
| 2021 | 915.6 Million USD | -32.74% |
| 2020 | 661.9 Million USD | 31.59% |
| 2019 | 612.9 Million USD | 3.98% |
| 2018 | 906 Million USD | -32.21% |
| 2017 | 1.13 Billion USD | -77.78% |
| 2016 | -4.18 Billion USD | 731.57% |
| 2015 | 754.3 Million USD | -36.51% |
| 2014 | 1.21 Billion USD | 39.48% |
| 2013 | 939.4 Million USD | 21.66% |
| 2012 | 858.9 Million USD | 20.05% |
| 2011 | 713.3 Million USD | 34.87% |
| 2010 | 594.1 Million USD | 32.55% |
| 2009 | 411.16 Million USD | 20.12% |
| 2008 | 325.31 Million USD | 64.39% |
| 2007 | 288.53 Million USD | -4.26% |
| 2006 | 157.12 Million USD | -64.17% |
| 2005 | 177.74 Million USD | 273.59% |
| 2004 | -293.9 Million USD | 21.42% |
| 2003 | 131.34 Million USD | -2.12% |
| 2002 | 111.3 Million USD | -7.35% |
| 2001 | 113.68 Million USD | 141.4% |
| 2000 | 49.41 Million USD | 26.38% |
| 1999 | 59.21 Million USD | 220.68% |
| 1998 | 45.17 Million USD | -132.17% |
| 1997 | -32.4 Million USD | 5.56% |
| 1996 | 95.4 Million USD | -3.83% |
| 1995 | 99.2 Million USD | -9.07% |
| 1994 | 109.1 Million USD | 22.72% |
| 1993 | 88.9 Million USD | 34.9% |
| 1992 | 65.9 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 104.9 Million USD | -53.31% |
| 2024 Q2 | 146.7 Million USD | 64.79% |
| 2023 Q4 | 177.6 Million USD | -3.53% |
| 2023 Q2 | 167.1 Million USD | 19.27% |
| 2023 Q1 | 140.1 Million USD | 4.55% |
| 2023 FY | - USD | 27.88% |
| 2023 Q3 | 184.1 Million USD | 10.17% |
| 2022 Q1 | 95.9 Million USD | -26.17% |
| 2022 FY | - USD | -42.27% |
| 2022 Q3 | 144.7 Million USD | 347.99% |
| 2022 Q4 | 134 Million USD | -7.39% |
| 2022 Q2 | 32.3 Million USD | -66.32% |
| 2021 Q3 | 497.8 Million USD | 75.16% |
| 2021 FY | - USD | -32.74% |
| 2021 Q1 | 141.1 Million USD | -79.18% |
| 2021 Q2 | 284.2 Million USD | 101.42% |
| 2021 Q4 | 129.9 Million USD | -73.91% |
| 2020 Q1 | 236.4 Million USD | -36.94% |
| 2020 Q4 | 677.7 Million USD | 531.59% |
| 2020 Q3 | 107.3 Million USD | -46.05% |
| 2020 FY | - USD | 31.59% |
| 2020 Q2 | 198.9 Million USD | -15.86% |
| 2019 FY | - USD | 3.98% |
| 2019 Q3 | 186.2 Million USD | -17.02% |
| 2019 Q4 | 374.9 Million USD | 101.34% |
| 2019 Q1 | 215.3 Million USD | 163.53% |
| 2019 Q2 | 224.4 Million USD | 4.23% |
| 2018 Q4 | 81.7 Million USD | -78.99% |
| 2018 FY | - USD | -32.21% |
| 2018 Q2 | 213.2 Million USD | -23.56% |
| 2018 Q1 | 278.9 Million USD | -1.73% |
| 2018 Q3 | 388.9 Million USD | 82.41% |
| 2017 Q1 | 322.6 Million USD | -89.99% |
| 2017 Q2 | 513.1 Million USD | 59.05% |
| 2017 Q3 | 300.5 Million USD | -41.43% |
| 2017 Q4 | 283.8 Million USD | -5.56% |
| 2017 FY | - USD | -77.78% |
| 2016 Q4 | 3.22 Billion USD | 57.58% |
| 2016 FY | - USD | 731.57% |
| 2016 Q2 | 397.1 Million USD | -51.8% |
| 2016 Q1 | 823.9 Million USD | 52.57% |
| 2016 Q3 | 2.04 Billion USD | 415.11% |
| 2015 Q1 | 201.4 Million USD | -38.2% |
| 2015 Q4 | 540 Million USD | 179.79% |
| 2015 FY | - USD | -36.51% |
| 2015 Q2 | 227.6 Million USD | 13.01% |
| 2015 Q3 | 193 Million USD | -15.2% |
| 2014 Q3 | 267.2 Million USD | -21.37% |
| 2014 FY | - USD | 39.48% |
| 2014 Q1 | 282.2 Million USD | -20.93% |
| 2014 Q2 | 339.8 Million USD | 20.41% |
| 2014 Q4 | 325.9 Million USD | 21.97% |
| 2013 Q3 | 231.6 Million USD | -7.84% |
| 2013 Q4 | 356.9 Million USD | 54.1% |
| 2013 Q1 | 223.09 Million USD | 9.67% |
| 2013 FY | - USD | 21.66% |
| 2013 Q2 | 251.29 Million USD | 12.64% |
| 2012 FY | - USD | 20.05% |
| 2012 Q3 | 191.27 Million USD | -2.52% |
| 2012 Q2 | 196.22 Million USD | 4.51% |
| 2012 Q1 | 187.75 Million USD | -2.74% |
| 2012 Q4 | 203.42 Million USD | 6.35% |
| 2011 Q1 | 122.91 Million USD | -23.09% |
| 2011 FY | - USD | 34.87% |
| 2011 Q4 | 193.05 Million USD | 41.67% |
| 2011 Q3 | 136.27 Million USD | -9.76% |
| 2011 Q2 | 151 Million USD | 22.85% |
| 2010 Q3 | 135.2 Million USD | 26.29% |
| 2010 Q4 | 159.8 Million USD | 18.2% |
| 2010 Q1 | 112.54 Million USD | -3.51% |
| 2010 Q2 | 107.06 Million USD | -4.88% |
| 2010 FY | - USD | 32.55% |
| 2009 Q1 | 93.9 Million USD | -0.96% |
| 2009 Q3 | 104.3 Million USD | 47.77% |
| 2009 Q4 | 116.63 Million USD | 11.82% |
| 2009 FY | - USD | 20.12% |
| 2009 Q2 | 70.58 Million USD | -24.83% |
| 2008 Q4 | 94.82 Million USD | 25.49% |
| 2008 Q1 | 121.68 Million USD | 92.28% |
| 2008 Q2 | 64.61 Million USD | -46.9% |
| 2008 Q3 | 75.56 Million USD | 16.95% |
| 2008 FY | - USD | 64.39% |
| 2007 Q4 | 63.28 Million USD | 4.71% |
| 2007 FY | - USD | -4.26% |
| 2007 Q1 | 53.08 Million USD | 34.09% |
| 2007 Q3 | 60.43 Million USD | 65.63% |
| 2007 Q2 | 36.48 Million USD | -31.27% |
| 2006 FY | - USD | -64.17% |
| 2006 Q4 | 39.59 Million USD | 1.12% |
| 2006 Q3 | 39.15 Million USD | -25.59% |
| 2006 Q2 | 52.61 Million USD | 21.1% |
| 2006 Q1 | 43.44 Million USD | -16.07% |
| 2005 Q2 | 390.83 Million USD | 1063.82% |
| 2005 FY | - USD | 273.59% |
| 2005 Q4 | 51.76 Million USD | 47.8% |
| 2005 Q3 | 35.02 Million USD | -91.04% |
| 2005 Q1 | 33.58 Million USD | 3.1% |
| 2004 Q2 | 19.45 Million USD | -41.79% |
| 2004 Q1 | 33.41 Million USD | -27.53% |
| 2004 FY | - USD | 21.42% |
| 2004 Q4 | 32.57 Million USD | -3.4% |
| 2004 Q3 | 33.71 Million USD | 73.35% |
| 2003 Q1 | 28.79 Million USD | -12.84% |
| 2003 Q4 | 46.1 Million USD | 42.41% |
| 2003 Q2 | 12.92 Million USD | -55.11% |
| 2003 Q3 | 32.37 Million USD | 150.43% |
| 2003 FY | - USD | -2.12% |
| 2002 Q3 | 37.87 Million USD | 72.12% |
| 2002 Q1 | 34 Million USD | -21.66% |
| 2002 FY | - USD | -7.35% |
| 2002 Q4 | 33.03 Million USD | -4.92% |
| 2002 Q2 | 23.65 Million USD | -27.14% |
| 2001 Q4 | 31.8 Million USD | 29.75% |
| 2001 Q1 | 19.81 Million USD | -42.45% |
| 2001 FY | - USD | 141.4% |
| 2001 Q2 | 12.69 Million USD | -53.48% |
| 2001 Q3 | 27.25 Million USD | 122.21% |
| 2000 Q1 | 15.97 Million USD | -34.8% |
| 2000 FY | - USD | 26.38% |
| 2000 Q3 | 22.6 Million USD | 320.68% |
| 2000 Q2 | -10.24 Million USD | -164.14% |
| 2000 Q4 | 26.73 Million USD | 102.66% |
| 1999 Q3 | 23.2 Million USD | 673.33% |
| 1999 FY | - USD | 220.68% |
| 1999 Q1 | 24.22 Million USD | 29.7% |
| 1999 Q2 | 3 Million USD | -88.55% |
| 1999 Q4 | 24.5 Million USD | 5.6% |
| 1998 Q4 | 19.5 Million USD | 410.77% |
| 1998 FY | - USD | -132.17% |
| 1998 Q2 | -121.6 Million USD | -548.71% |
| 1998 Q1 | 25.4 Million USD | -23.01% |
| 1998 Q3 | -7.5 Million USD | 94.65% |
| 1997 FY | - USD | 5.56% |
| 1997 Q3 | 30.1 Million USD | 52.15% |
| 1997 Q2 | 20.9 Million USD | -19.31% |
| 1997 Q1 | 25.9 Million USD | -11.6% |
| 1997 Q4 | 33.1 Million USD | 10.69% |
| 1996 Q3 | 26.7 Million USD | 227.59% |
| 1996 Q2 | 8.7 Million USD | -69.58% |
| 1996 Q1 | 26.8 Million USD | -9.78% |
| 1996 FY | - USD | -3.83% |
| 1996 Q4 | 29.3 Million USD | 2.81% |
| 1995 FY | - USD | -9.07% |
| 1995 Q3 | 30.2 Million USD | 95.83% |
| 1995 Q2 | 16.8 Million USD | -35.14% |
| 1995 Q4 | 29.7 Million USD | -3.65% |
| 1995 Q1 | 25.9 Million USD | -3.0% |
| 1994 Q4 | 26.7 Million USD | -10.7% |
| 1994 FY | - USD | 22.72% |
| 1994 Q3 | 29.9 Million USD | 26.16% |
| 1994 Q1 | 26.7 Million USD | -10.4% |
| 1994 Q2 | 23.7 Million USD | -11.24% |
| 1993 FY | - USD | 34.9% |
| 1993 Q1 | 22.5 Million USD | -1.75% |
| 1993 Q2 | 22.6 Million USD | 0.44% |
| 1993 Q3 | 28.9 Million USD | 27.88% |
| 1993 Q4 | 29.8 Million USD | 3.11% |
| 1992 Q4 | 22.9 Million USD | 10.1% |
| 1992 Q1 | 17.9 Million USD | 12.58% |
| 1992 Q2 | 17.4 Million USD | -2.79% |
| 1992 Q3 | 20.8 Million USD | 19.54% |
| 1992 FY | - USD | 0.0% |
| 1991 Q4 | 15.9 Million USD | -81.75% |
| 1991 Q3 | 87.1 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 496.157% |
| Dynavax Technologies Corporation | 9.66 Million USD | -6585.289% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -557.63% |
| Illumina, Inc. | -608 Million USD | 206.283% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 94.017% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 243.916% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 105.73% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 80.154% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 722.591% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 86.116% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 1833.23% |
| Waters Corporation | 1.02 Billion USD | 36.787% |
| Biogen Inc. | 2.37 Billion USD | 72.814% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 839.131% |
| Evolus, Inc. | -41.81 Million USD | 1645.563% |
| Adicet Bio, Inc. | -136.53 Million USD | 573.285% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 649.256% |
| bluebird bio, Inc. | -167.16 Million USD | 486.573% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 530.49% |
| FibroGen, Inc. | -261.4 Million USD | 347.203% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 61.467% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 1554.203% |
| Homology Medicines, Inc. | -47.75 Million USD | 1453.128% |
| Geron Corporation | -174.78 Million USD | 469.718% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 383.271% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 801.789% |
| Myriad Genetics, Inc. | -67.8 Million USD | 1053.097% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 740.9% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 227.628% |
| Zoetis Inc. | 3.68 Billion USD | 82.464% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 1377.782% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 44.487% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -108.261% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 85.968% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 1890.921% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 380.944% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 342.935% |
| Verastem, Inc. | -83.16 Million USD | 877.0% |
| Nektar Therapeutics | -243.1 Million USD | 365.809% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 387.211% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 834.443% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 247.132% |
| OPKO Health, Inc. | -65.51 Million USD | 1086.324% |
| Exelixis, Inc. | 196.6 Million USD | -228.684% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -55.299% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -496.544% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 1258.978% |
| uniQure N.V. | -253.1 Million USD | 355.314% |
| Imunon, Inc. | -20.78 Million USD | 3209.38% |
| Blueprint Medicines Corporation | -474.61 Million USD | 236.153% |
| Insmed Incorporated | -654.73 Million USD | 198.696% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -42.981% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 287.052% |
| TG Therapeutics, Inc. | 26.1 Million USD | -2375.862% |
| Incyte Corporation | 919.42 Million USD | 29.717% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 227.884% |